Swati B. GuptaChristopher T. MastNathan D. WolfeVlad NovitskySheri A. DubeyEsper G. KallasMauro SchechterBernard MbeweEftyhia VardasPunee PitisuttithumDonald BurkeDan FreedRobin MoggPaul M. CoplanJon H. CondraRomnie S. LongKiersten AndersonDanilo R. CasimiroJohn W. ShiverWalter L. StrausMerck & Co., Inc.Johns Hopkins Bloomberg School of Public HealthHarvard School of Public HealthUniversidade Federal de Sao PauloUniversidade Federal do Rio de JaneiroMalawi College of MedicineMinistry of Population and HealthUniversity of WitwatersrandMahidol UniversityIntl. Partnership for MicrobicidesMerck Research Laboratories2018-08-202018-08-202006-06-01Journal of Acquired Immune Deficiency Syndromes. Vol.42, No.2 (2006), 135-139152541352-s2.0-33745092368https://repository.li.mahidol.ac.th/handle/123456789/23745An effective HIV type 1 (HIV-1) vaccine will likely require elicitation of broadly reactive cell-mediated immune (CMI) responses against divergent HIV-1 clades. We compared anti-HIV-1 T-cell immune responses among 363 unvaccinated adults infected with diverse HIV-1 clades. Response rates to clade B Gag and/or clade B Nef in Botswana (95%) and Cameroon (98%) were similar when compared with those in countries previously studied, including Brazil (92%), Thailand (96%), South Africa (96%), Malawi (100%), and the United States (100%). Substantial cross-clade cell-mediated immune responses in Botswana and Cameroon confirm previous findings in a larger, more genetically diverse collection of HIV-1 samples. Copyright © 2006 by Lippincott Williams & Wilkins.Mahidol UniversityMedicineArticleSCOPUS10.1097/01.qai.0000223017.01568.e7